Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Top Performance

Predictions

buy
Pro-Dex Inc.

Start price
Target price
Perf. (%)
€13.30
15.10.23
-
15.10.24
33.83%
17.05.24

StockNews.com 
15.10.23 50%
buy
Orasure Tech

Start price
Target price
Perf. (%)
€5.05
14.10.23
-
14.10.24
-5.35%
17.05.24

StockNews.com 
14.10.23 50%
sell
T2 Biosystems Inc.

Start price
Target price
Perf. (%)
€0.16
14.10.23
-
14.10.24
0.00%
20.11.23

StockNews.com 
14.10.23 50%
buy
Addus Homecare Corp.

Start price
Target price
Perf. (%)
€77.50
07.10.23
-
07.10.24
29.03%
17.05.24

StockNews.com 
07.10.23 50%
buy
Pro-Dex Inc.

Start price
Target price
Perf. (%)
€13.90
07.10.23
-
07.10.24
28.06%
17.05.24

StockNews.com 
07.10.23 50%
buy
Ocular Therapeutix Inc.

Start price
Target price
Perf. (%)
€2.76
04.10.23
€11.40
04.10.24
101.45%
17.05.24

HC Wainwright 
04.10.23 50%
buy
Accuray Inc.

Start price
Target price
Perf. (%)
€2.76
04.10.23
€7.12
04.10.24
-44.20%
16.05.24

B. Riley 
04.10.23 50%
sell
Avinger Inc.

Start price
Target price
Perf. (%)
€0.34
01.10.23
-
01.10.24
0.00%
20.11.23

StockNews.com 
01.10.23 50%
sell
US Physical Therapy Inc.

Start price
Target price
Perf. (%)
€86.50
30.09.23
-
30.09.24
13.06%
17.05.24

StockNews.com 
30.09.23 50%
buy
Addus Homecare Corp.

Start price
Target price
Perf. (%)
€79.50
30.09.23
-
30.09.24
25.79%
17.05.24

StockNews.com 
30.09.23 50%
buy
Atricure Inc.

Start price
Target price
Perf. (%)
€59.50
29.09.23
€52.82
29.09.24
-
30.09.21

UBS Group AG 
29.09.23 50%
buy
Pacific Biosciences of California Inc.

Start price
Target price
Perf. (%)
€7.97
28.09.23
€10.46
28.09.24
-76.57%
08:22

Sanford C. Bernstein 
28.09.23 50%
buy
MicroVision Inc

Start price
Target price
Perf. (%)
€2.11
27.09.23
€4.00
27.09.24
5.76%
23.11.23

Fair valuation
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Traumtanz 
27.09.23 50%
buy
Motus GI Holdings Inc.

Start price
Target price
Perf. (%)
€0.41
27.09.23
€2.37
27.09.24
35.14%
20.11.23

HC Wainwright 
27.09.23 50%
buy
SI-BONE Inc

Start price
Target price
Perf. (%)
€19.30
26.09.23
€28.37
26.09.24
-28.50%
17.05.24

Cantor Fitzgerald 
26.09.23 50%
buy
Sientra Inc.

Start price
Target price
Perf. (%)
€2.52
25.09.23
€5.20
25.09.24
-23.41%
11.10.23

Could be very worthwhile Investment >20% year
DomRuinart 
25.09.23 50%
sell
Avinger Inc.

Start price
Target price
Perf. (%)
€0.34
23.09.23
-
23.09.24
0.00%
20.11.23

StockNews.com 
23.09.23 50%
buy
R1 RCM Inc.

Start price
Target price
Perf. (%)
€14.40
22.09.23
€20.64
22.09.24
-22.22%
17.05.24

Royal Bank of Canada 
22.09.23 50%
buy
R1 RCM Inc.

Start price
Target price
Perf. (%)
€14.00
22.09.23
€18.76
22.09.24
-20.00%
17.05.24

Citigroup Inc. 
22.09.23 50%
buy
Vita 34 AG

Start price
Target price
Perf. (%)
€4.76
19.09.23
€6.00
19.09.24
-1.68%
30.09.23

Very Future proof/growth oriented business model
Market Leader or Top 3
Could be very worthwhile Investment >20% year
Rising EBIT margin expected
kostojunior 
19.09.23 30%
buy
US Physical Therapy Inc.

Start price
Target price
Perf. (%)
€89.50
19.09.23
-
19.09.24
9.27%
17.05.24

CJS Securities 
19.09.23 50%
sell
MicroVision Inc

Start price
Target price
Perf. (%)
€2.02
19.09.23
€4.00
19.09.24
4.43%
27.09.23

Fair valuation
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Traumtanz 
19.09.23 50%
sell
Cytosorbents Corp.

Start price
Target price
Perf. (%)
€1.83
17.09.23
-
17.09.24
-52.14%
19.01.24

Probably not worthwhile Investment
Lokrim 
17.09.23 20%
buy
Staar Surgical Co.

Start price
Target price
Perf. (%)
€40.69
15.09.23
€48.71
15.09.24
-3.66%
16.05.24

Needham & Company LLC 
15.09.23 50%
buy
Ocular Therapeutix Inc.

Start price
Target price
Perf. (%)
€3.41
14.09.23
€16.88
14.09.24
66.71%
17.05.24

Robert W. Baird 
14.09.23 50%